New drug PB shows promise for slowing excessive urination in kidney patients
NCT ID NCT05190744
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether the medication PB can safely reduce excessive urination in people with certain kidney diseases, including inherited nephrogenic diabetes insipidus, lithium-induced diabetes insipidus, and polycystic kidney disease treated with tolvaptan. Researchers measured changes in urine concentration and daily urine output over time. The study enrolled 36 adults and was completed in Phase 2.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic
Jacksonville, Florida, 32224, United States